<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01352637</url>
  </required_header>
  <id_info>
    <org_study_id>1005011047</org_study_id>
    <nct_id>NCT01352637</nct_id>
  </id_info>
  <brief_title>Enhancing Exposure Therapy for Post Traumatic Stress Disorder (PTSD): Virtual Reality and Imaginal Exposure With a Cognitive Enhancer</brief_title>
  <official_title>Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure With a Cognitive Enhancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Long Beach Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Intrepid Center of Excellence</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the differences between four active treatment conditions
      for combat-related Post Traumatic Stress Disorder (PTSD): virtual reality exposure therapy
      (VRE) or prolonged imaginal exposure therapy (PE), both with DCS or placebo, as well as to
      examine predictors for PTSD and response to treatment in active duty military personnel,
      veterans, and civilians who served in Iraq and Afghanistan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post Traumatic Stress Disorder (PTSD) is an anxiety disorder that can develop following
      exposure to traumatic events and includes symptoms of re-experiencing the trauma, such as
      through nightmares and flashbacks, avoidance and numbing, and physical hyperarousal. PTSD has
      been estimated to affect 10-20% of returning Operation Iraqi Freedom (OIF)/Operation Enduring
      Freedom (OEF) veterans. The most effective intervention found for PTSD is exposure therapy,
      which can be delivered in different formats, e. g. via virtual reality (VR) and as imaginal
      exposure. The goal of this study is to test the difference between 4 study conditions:
      virtual reality exposure therapy (VRE) or prolonged imaginal exposure therapy (PE), both
      combined with an antibiotic drug, DCS (active pill vs. placebo). D-Cycloserine (DCS), a drug
      that has been FDA approved for over 20 years, has been hypothesized to enhance the
      therapeutic effects of exposure therapy.). A secondary purpose of this study is to examine
      predictors for PTSD and response to PTSD intervention in active duty military personnel,
      veterans, and civilians who served in Iraq/Afghanistan. Psychophysiological factors (e.g.
      heart rate, blood pressure) and/or a genetic polymorphism (BDNF Val66Met) obtained from a
      saliva sample will be examined.

      The two primary co-aims are

        1. to examine the effects of DCS versus placebo (PLA) augmentation of exposure therapy on
           PTSD symptoms, and

        2. to examine the relative efficacy of virtual reality enhanced exposure therapy (VRE) and
           exposure therapy (PE) on PTSD symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2011</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The two primary co-aims of this study are
to examine the effects of DCS versus placebo (PLA) augmentation of exposure therapy on PTSD symptoms and
to examine the relative efficacy of virtual reality enhanced exposure therapy (VRE) and exposure therapy (PE) on PTSD symptoms.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CAPS-IV at the End of Treatment</measure>
    <time_frame>after weekly treatment session 9 (at posttreatment assessment)</time_frame>
    <description>Clinician Administered PTSD Scale (CAPS) for the DSM-IV [34]. The CAPS-IV is a structured clinical interview designed to assess the 17 DSM-IV PTSD symptoms. CAPS-IV provides categorical ratings of diagnostic status as well as a quantitative index of symptom severity. The CAPS total severity score is based on response to the 17 items that assess the frequency and intensity of current PTSD symptoms. Symptom severity is assessed separately for past month and past week time frames.
CAPS-IV range is 0-136, higher scores mean a worse outcome.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">192</enrollment>
  <condition>Post Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo + Prolonged Imaginal Exposure</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo (sugar pill) + Prolonged Imaginal Exposure (PE) PTSD treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + VR exposure</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo (sugar pill) + Virtual Reality Exposure (VR) PTSD treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DCS + Prolonged Imaginal Exposure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: 50mg DCS (D-Cycloserine ) + Prolonged Imaginal Exposure (PE) PTSD treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DCS+VR exposure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: 50mg DCS (D-Cycloserine ) + Virtual Reality Exposure (VR) PTSD treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCS (D-Cycloserine ) + Prolonged Imaginal Exposure</intervention_name>
    <description>50mg DCS (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure</description>
    <arm_group_label>DCS + Prolonged Imaginal Exposure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCS (D-Cycloserine ) + Virtual Reality Exposure</intervention_name>
    <description>50mg DCS (taken once a week on the day of the therapy session) + Virtual Reality Exposure</description>
    <arm_group_label>DCS+VR exposure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + Prolonged Imaginal Exposure</intervention_name>
    <description>Placebo (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure</description>
    <arm_group_label>Placebo + Prolonged Imaginal Exposure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (sugar pill) + Virtual Reality Exposure</intervention_name>
    <description>Placebo (taken once a week on the day of the therapy session) + Virtual Reality Exposure</description>
    <arm_group_label>Placebo + VR exposure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of OEF-OIF (Operations Enduring Freedom or Iraqi Freedom) Combat Related
             PTSD;

          2. Female participants of childbearing potential must agree to use an effective method of
             birth control (i.e., oral contraceptive, Norplant, diaphragm, condom, or spermicide)
             during the course of the study, or to remain abstinent from sex, to ensure they do not
             become pregnant during the course of the study;

          3. Ability to provide informed consent and function at an intellectual level sufficient
             to allow accurate completion of all assessment instruments;

          4. Participants must be literate in English;

          5. Patients must be medically healthy and willing to take the study drug;

          6. VRE stimuli available must be consistent with subject's trauma.

        Exclusion Criteria:

          1. Lifetime or current diagnosis of schizophrenia or other psychotic disorder, bipolar
             disorder;

          2. Participation in a clinical trial during the previous 3 months;

          3. Current evidence or history of significant unstable medical illness or organic brain
             impairment, including stroke, CNS tumor, demyelinating disease, cardiac, pulmonary,
             gastrointestinal, renal or hepatic impairment;

          4. Patients who in the investigator's judgment pose a current suicidal or homicidal risk;

          5. Alcohol, medication, or illegal substance dependence within the past 90 days;

          6. Treatment with any other concomitant medication with primarily CNS activity, or
             treatment with any medication that the PI judges not acceptable for this study;

          7. history of seizures;

          8. Pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JoAnn Difede, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara Rothbaum, Ph.D., ABPP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Skip Rizzo, Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center/National Intrepid Center of Excellence (NICoE)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://www.patss.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 18, 2011</study_first_submitted>
  <study_first_submitted_qc>May 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2011</study_first_posted>
  <results_first_submitted>May 6, 2019</results_first_submitted>
  <results_first_submitted_qc>June 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2019</results_first_posted>
  <last_update_submitted>June 13, 2019</last_update_submitted>
  <last_update_submitted_qc>June 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Traumatic Event</keyword>
  <keyword>Trauma Survivor</keyword>
  <keyword>Exposure Therapy</keyword>
  <keyword>PTSD DCS</keyword>
  <keyword>Virtual Reality Exposure</keyword>
  <keyword>Veteran</keyword>
  <keyword>Combat-related PTSD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 27, 2010</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT01352637/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Total sample size is n=192. Randomization allocation ratio was 1:1:1:1 to VRE vs. PE and DCS vs. placebo.
Study had 2 co-primary aims to examine:
the effects of DCS (n=95) vs placebo (n=97) augmentation of exposure therapy
the relative efficacy of VRE (n=97) and PE (n=95) on PTSD symptoms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Virtual Reality Exposure (VRE)</title>
          <description>Virtual Reality Exposure (VRE): PTSD treatment</description>
        </group>
        <group group_id="P2">
          <title>Prolonged Imaginal Exposure (PE)</title>
          <description>Drug: Placebo (sugar pill) + Virtual Reality Exposure (VR) PTSD treatment
Prolonged Imaginal Exposure (PE): PTSD treatment</description>
        </group>
        <group group_id="P3">
          <title>Drug: D-Cycloserine (DCS)</title>
          <description>D-Cycloserine (DCS) (taken once a week on the day of the therapy session)</description>
        </group>
        <group group_id="P4">
          <title>Drug: Placebo</title>
          <description>Drug: Placebo (sugar pill) (taken once a week on the day of the therapy session)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Exposure Therapy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Drug</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="95"/>
                <participants group_id="P4" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="70"/>
                <participants group_id="P4" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Total sample size is n=192. Randomization allocation ratio was 1:1:1:1 to VRE vs. PE and DCS vs. placebo.
Study had 2 co-primary aims to examine:
the effects of DCS (n=95) vs placebo (n=97) augmentation of exposure therapy
the relative efficacy of VRE (n=97) and PE (n=95) on PTSD symptoms.</population>
      <group_list>
        <group group_id="B1">
          <title>Virtual Reality Exposure (VRE)+Drug: DCycloserine (DCS)</title>
          <description>Virtual Reality Exposure (VRE): PTSD treatment + D-Cycloserine (DCS) (taken once a week on the day of the therapy session)</description>
        </group>
        <group group_id="B2">
          <title>Prolonged Imaginal Exposure (PE)+Drug: DCycloserine (DCS)</title>
          <description>Prolonged Imaginal Exposure (PE): PTSD treatment + D-Cycloserine (DCS) (taken once a week on the day of the therapy session)</description>
        </group>
        <group group_id="B3">
          <title>Virtual Reality Exposure (VRE)+Drug: Placebo</title>
          <description>Virtual Reality Exposure (VRE): PTSD treatment + Placebo (sugar pill) (taken once a week on the day of the therapy session)</description>
        </group>
        <group group_id="B4">
          <title>Prolonged Imaginal Exposure (PE)+Drug: Placebo</title>
          <description>Prolonged Imaginal Exposure (PE): PTSD treatment + Placebo (sugar pill) (taken once a week on the day of the therapy session)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="47"/>
            <count group_id="B5" value="192"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.74" spread="7.69"/>
                    <measurement group_id="B2" value="36.17" spread="8.53"/>
                    <measurement group_id="B3" value="34.80" spread="6.99"/>
                    <measurement group_id="B4" value="33.70" spread="7.95"/>
                    <measurement group_id="B5" value="34.62" spread="7.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American/Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CAPS-IV, past week</title>
          <description>Clinician Administered PTSD Scale (CAPS) for the DSM-IV [34]. The CAPS-IV is a structured clinical interview designed to assess the 17 DSM-IV PTSD symptoms. CAPS-IV provides categorical ratings of diagnostic status as well as a quantitative index of symptom severity. The CAPS total severity score is based on response to the 17 items that assess the frequency and intensity of current PTSD symptoms. Symptom severity is assessed separately for past month and past week time frames.
CAPS-IV range is 0-136, higher scores mean a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.72" spread="19.98"/>
                    <measurement group_id="B2" value="75.08" spread="18.69"/>
                    <measurement group_id="B3" value="74.46" spread="19.11"/>
                    <measurement group_id="B4" value="70.74" spread="200.37"/>
                    <measurement group_id="B5" value="73.04" spread="19.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CAPS-IV at the End of Treatment</title>
        <description>Clinician Administered PTSD Scale (CAPS) for the DSM-IV [34]. The CAPS-IV is a structured clinical interview designed to assess the 17 DSM-IV PTSD symptoms. CAPS-IV provides categorical ratings of diagnostic status as well as a quantitative index of symptom severity. The CAPS total severity score is based on response to the 17 items that assess the frequency and intensity of current PTSD symptoms. Symptom severity is assessed separately for past month and past week time frames.
CAPS-IV range is 0-136, higher scores mean a worse outcome.</description>
        <time_frame>after weekly treatment session 9 (at posttreatment assessment)</time_frame>
        <population>Total sample size is n=192. Randomization allocation ratio was 1:1:1:1 to VRE vs. PE and DCS vs. placebo.
Study had 2 co-primary aims to examine:
the effects of DCS (n=95) vs placebo (n=97) augmentation of exposure therapy
the relative efficacy of VRE (n=97) and PE (n=95) on PTSD symptoms.</population>
        <group_list>
          <group group_id="O1">
            <title>Virtual Reality Exposure (VRE)</title>
            <description>Virtual Reality Exposure (VRE): PTSD treatment</description>
          </group>
          <group group_id="O2">
            <title>Prolonged Imaginal Exposure (PE)</title>
            <description>Prolonged Imaginal Exposure (PE): PTSD treatment</description>
          </group>
          <group group_id="O3">
            <title>Drug: D-Cycloserine (DCS)</title>
            <description>D-Cycloserine (DCS) (taken once a week on the day of the therapy session)</description>
          </group>
          <group group_id="O4">
            <title>Drug: Placebo</title>
            <description>Drug: Placebo (sugar pill) (taken once a week on the day of the therapy session)</description>
          </group>
        </group_list>
        <measure>
          <title>CAPS-IV at the End of Treatment</title>
          <description>Clinician Administered PTSD Scale (CAPS) for the DSM-IV [34]. The CAPS-IV is a structured clinical interview designed to assess the 17 DSM-IV PTSD symptoms. CAPS-IV provides categorical ratings of diagnostic status as well as a quantitative index of symptom severity. The CAPS total severity score is based on response to the 17 items that assess the frequency and intensity of current PTSD symptoms. Symptom severity is assessed separately for past month and past week time frames.
CAPS-IV range is 0-136, higher scores mean a worse outcome.</description>
          <population>Total sample size is n=192. Randomization allocation ratio was 1:1:1:1 to VRE vs. PE and DCS vs. placebo.
Study had 2 co-primary aims to examine:
the effects of DCS (n=95) vs placebo (n=97) augmentation of exposure therapy
the relative efficacy of VRE (n=97) and PE (n=95) on PTSD symptoms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.42" spread="26.55"/>
                    <measurement group_id="O2" value="50.61" spread="25.22"/>
                    <measurement group_id="O3" value="54.20" spread="26.72"/>
                    <measurement group_id="O4" value="48.59" spread="24.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During treatment (9 weekly therapy sessions).</time_frame>
      <desc>18-item Side Effect Screening Checklist was administered at each therapy session to identify possible medication-related side effects and specific adverse symptoms.</desc>
      <group_list>
        <group group_id="E1">
          <title>Virtual Reality Exposure (VRE)</title>
          <description>Virtual Reality Exposure (VRE): PTSD treatment</description>
        </group>
        <group group_id="E2">
          <title>Prolonged Imaginal Exposure (PE)</title>
          <description>Prolonged Imaginal Exposure (PE): PTSD treatment</description>
        </group>
        <group group_id="E3">
          <title>Drug: D-Cycloserine (DCS)</title>
          <description>D-Cycloserine (DCS) (taken once a week on the day of the therapy session)</description>
        </group>
        <group group_id="E4">
          <title>Drug: Placebo</title>
          <description>Drug: Placebo (sugar pill) (taken once a week on the day of the therapy session)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Cellulitis of the lower extremity</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hopitalization</sub_title>
                <description>Injuries due to car accident</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Chest pains and shortness of breath</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. JoAnn Difede</name_or_title>
      <organization>Weill Cornell Medical College</organization>
      <phone>212 746 3079</phone>
      <email>jdifede@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

